Cargando…
Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
BACKGROUND: This study aimed to examine the impact of baseline eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio on clinical outcomes of patients with acute coronary syndrome. METHODS AND RESULTS: In the HIJ‐PROPER (Heart Institute of Japan Proper Level of Lipid Lowering With Pitavastatin a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759903/ https://www.ncbi.nlm.nih.gov/pubmed/31390907 http://dx.doi.org/10.1161/JAHA.119.012953 |
_version_ | 1783453782350233600 |
---|---|
author | Arashi, Hiroyuki Yamaguchi, Junichi Kawada‐Watanabe, Erisa Koyanagi, Ryo Sekiguchi, Haruki Mori, Fumiaki Haruta, Shoji Ishii, Yasuhiro Murasaki, Satoshi Suzuki, Kazuhito Yamauchi, Takao Ogawa, Hiroshi Hagiwara, Nobuhisa |
author_facet | Arashi, Hiroyuki Yamaguchi, Junichi Kawada‐Watanabe, Erisa Koyanagi, Ryo Sekiguchi, Haruki Mori, Fumiaki Haruta, Shoji Ishii, Yasuhiro Murasaki, Satoshi Suzuki, Kazuhito Yamauchi, Takao Ogawa, Hiroshi Hagiwara, Nobuhisa |
author_sort | Arashi, Hiroyuki |
collection | PubMed |
description | BACKGROUND: This study aimed to examine the impact of baseline eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio on clinical outcomes of patients with acute coronary syndrome. METHODS AND RESULTS: In the HIJ‐PROPER (Heart Institute of Japan Proper Level of Lipid Lowering With Pitavastatin and Ezetimibe in Acute Coronary Syndrome) study, 1734 patients with acute coronary syndrome and dyslipidemia were randomly assigned to pitavastatin+ezetimibe therapy or pitavastatin monotherapy. We divided the patients into 2 groups based on EPA/AA ratio on admission (cutoff 0.34 μg/mL as median of baseline EPA/AA ratio) and examined their clinical outcomes. The primary end point comprised all‐cause death, nonfatal myocardial infarction, nonfatal stroke, unstable angina pectoris, or ischemia‐driven revascularization. Percentage reduction of low‐density lipoprotein cholesterol and triglyceride from baseline to follow‐up was similar regardless of baseline EPA/AA ratio. Despite the mean low‐density lipoprotein cholesterol level during follow‐up being similar between the low‐ and high‐EPA/AA groups, the mean triglyceride levels during follow‐up were significantly higher in the low‐ than in the high‐EPA/AA group. After 3 years of follow‐up, the cumulative incidence of the primary end point in patients with low EPA/AA was 27.2% in the pitavastatin+ezetimibe group compared with 36.6% in the pitavastatin‐monotherapy group (hazard ratio 0.69; 95% CI, 0.52‐0.93; P=0.015). However, there was no effect of pitavastatin+ezetimibe therapy on the primary end point in patients with high EPA/AA (hazard ratio 0.92; 95% CI, 0.70‐1.20; P=0.52). CONCLUSIONS: Among acute coronary syndrome patients who have dyslipidemia and low EPA/AA ratio, adding ezetimibe to statin decreases the risk of cardiovascular events compared with statin monotherapy. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/ctr. Unique identifier: UMIN000002742 |
format | Online Article Text |
id | pubmed-6759903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67599032019-09-30 Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER Arashi, Hiroyuki Yamaguchi, Junichi Kawada‐Watanabe, Erisa Koyanagi, Ryo Sekiguchi, Haruki Mori, Fumiaki Haruta, Shoji Ishii, Yasuhiro Murasaki, Satoshi Suzuki, Kazuhito Yamauchi, Takao Ogawa, Hiroshi Hagiwara, Nobuhisa J Am Heart Assoc Original Research BACKGROUND: This study aimed to examine the impact of baseline eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio on clinical outcomes of patients with acute coronary syndrome. METHODS AND RESULTS: In the HIJ‐PROPER (Heart Institute of Japan Proper Level of Lipid Lowering With Pitavastatin and Ezetimibe in Acute Coronary Syndrome) study, 1734 patients with acute coronary syndrome and dyslipidemia were randomly assigned to pitavastatin+ezetimibe therapy or pitavastatin monotherapy. We divided the patients into 2 groups based on EPA/AA ratio on admission (cutoff 0.34 μg/mL as median of baseline EPA/AA ratio) and examined their clinical outcomes. The primary end point comprised all‐cause death, nonfatal myocardial infarction, nonfatal stroke, unstable angina pectoris, or ischemia‐driven revascularization. Percentage reduction of low‐density lipoprotein cholesterol and triglyceride from baseline to follow‐up was similar regardless of baseline EPA/AA ratio. Despite the mean low‐density lipoprotein cholesterol level during follow‐up being similar between the low‐ and high‐EPA/AA groups, the mean triglyceride levels during follow‐up were significantly higher in the low‐ than in the high‐EPA/AA group. After 3 years of follow‐up, the cumulative incidence of the primary end point in patients with low EPA/AA was 27.2% in the pitavastatin+ezetimibe group compared with 36.6% in the pitavastatin‐monotherapy group (hazard ratio 0.69; 95% CI, 0.52‐0.93; P=0.015). However, there was no effect of pitavastatin+ezetimibe therapy on the primary end point in patients with high EPA/AA (hazard ratio 0.92; 95% CI, 0.70‐1.20; P=0.52). CONCLUSIONS: Among acute coronary syndrome patients who have dyslipidemia and low EPA/AA ratio, adding ezetimibe to statin decreases the risk of cardiovascular events compared with statin monotherapy. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/ctr. Unique identifier: UMIN000002742 John Wiley and Sons Inc. 2019-08-08 /pmc/articles/PMC6759903/ /pubmed/31390907 http://dx.doi.org/10.1161/JAHA.119.012953 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Arashi, Hiroyuki Yamaguchi, Junichi Kawada‐Watanabe, Erisa Koyanagi, Ryo Sekiguchi, Haruki Mori, Fumiaki Haruta, Shoji Ishii, Yasuhiro Murasaki, Satoshi Suzuki, Kazuhito Yamauchi, Takao Ogawa, Hiroshi Hagiwara, Nobuhisa Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER |
title | Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
|
title_full | Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
|
title_fullStr | Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
|
title_full_unstemmed | Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
|
title_short | Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ‐PROPER
|
title_sort | polyunsaturated fatty acid impact on clinical outcomes in acute coronary syndrome patients with dyslipidemia: subanalysis of hij‐proper |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759903/ https://www.ncbi.nlm.nih.gov/pubmed/31390907 http://dx.doi.org/10.1161/JAHA.119.012953 |
work_keys_str_mv | AT arashihiroyuki polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT yamaguchijunichi polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT kawadawatanabeerisa polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT koyanagiryo polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT sekiguchiharuki polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT morifumiaki polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT harutashoji polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT ishiiyasuhiro polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT murasakisatoshi polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT suzukikazuhito polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT yamauchitakao polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT ogawahiroshi polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper AT hagiwaranobuhisa polyunsaturatedfattyacidimpactonclinicaloutcomesinacutecoronarysyndromepatientswithdyslipidemiasubanalysisofhijproper |